Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.34, $0.25 better than the analyst estimate of $2.09. Revenue for the quarter came in at $984.2 million versus the consensus estimate of $941.47 million.

GUIDANCE:

Charles River Laboratories sees FY2025 EPS of $9.30-$9.80, versus the consensus of $9.31.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.